- Case report
- Open Access
- Open Peer Review
Visceral larva migrans associated with earthworm and gecko ingestion: a case report
© Yu et al.; licensee BioMed Central Ltd. 2012
- Received: 3 January 2012
- Accepted: 18 July 2012
- Published: 18 July 2012
Visceral larva migrans is a syndrome caused by an infection with larval helminths, which may result in partial or general pathological changes in host tissues. Due to the difficulty in finding the causative parasites, the diagnosis of visceral larva migrans is generally based on compatible clinical signs, epidemic history, marked eosinophilia and pathological examination, especially positive serological test results and the disappearance of symptoms after specific treatment.
We report here the case of a 21-year-old Chinese man who, having ingested living earthworms and geckos at a witch’s suggestion, presented with fatigue and wordlessness lasting for one year along with elevated transaminase levels for one month. Clinical examination showed eosinophilia, elevated transaminase levels, nodular lesions in his liver and typical pathological characteristics of hepatic visceral larva migrans. After four courses of anthelmintic therapy, our patient presented with sustaining improvement of clinical manifestations and normalization of laboratory data.
Because of the difficulty in making a definite diagnosis, anthelmintic therapy should be performed in patients with a suspected diagnosis of visceral larva migrans based on their epidemic history and presence of typical manifestations, especially when the serological test results are negative. Furthermore, patients with severe parasite infection may require multiple anthelmintic therapies in order to eliminate the parasites.
- Indirect Bilirubin
- Elevated Transaminase Level
- Trichuris Trichiura
Visceral larva migrans (VLM) is a syndrome caused by an infection with larval helminths. They invade aberrant hosts, such as human beings, but instead of developing into adult worms, they migrate through host tissues, resulting in partial or general pathological changes. A cause of zoonosis, the parasites can finish their natural life cycles in free-living form, which is vital for maintaining their infection capability. While VLM has a worldwide distribution, it is most commonly seen in the tropical and developing countries, where the sanitary and hygienic conditions are poor.
The clinical manifestations of VLM are varied, depending on which organs are involved. Common clinical manifestations are marked eosinophilia and hyperglobulinemia, caused by the host immune response to the larval helminths . Due to the difficulty in finding the causative parasites, the diagnosis of VLM is generally based on compatible clinical signs, epidemic history, marked eosinophilia and pathological examination, especially positive serological test results and the disappearance of symptoms after specific treatment . Here, we report a case in which the patient was suspected of VLM associated with more than one kind of parasitic infection, caused by the ingestion of earthworms and geckos.
A 21-year-old Chinese man presented to our hospital with fatigue and wordlessness lasting for one year along with elevated transaminase levels for one month. One year before presentation, suffering from work and love problems, our patient had begun to complain of fatigue accompanied by wordlessness, low mood, occasional vomiting and anorexia. Subsequently, he had been diagnosed with depression disorder and had received anti-depression therapy in his native hospital several times, but to little effect. He turned to a native witch and ingested living earthworms and geckos for 10 days at her suggestion. One month before his admission to our hospital, a laboratory evaluation revealed that his transaminase level was elevated. He denied fever, jaundice, abdominal pain, melena, changes in bowel habits, chest pain, respiratory symptoms or visual changes. Furthermore, in the previous year he had unintentionally lost 25kg in weight. Nothing notable was found in his medical history or previous drug therapy.
His physical examination demonstrated malnutrition, scythropasmus and low voice. No skin eruption was observed. His heart, lung and abdominal examination showed no sign of any abnormality. A neurologic examination did not reveal any focal deficits.
According to these findings, parasitic infection accompanied by VLM was suspected, combined with depression disorder. A course of albendazole was administrated at a dosage of 400mg once daily for 14 days. One month later, a laboratory examination was conducted and showed WBC 10.4 × 109/L, with 18.14% eosinophils, ALT 88U/L, AST 65U/L, GGT 95U/L, TB 31.2μmol/L, DB 16.0μmol/L and IB 15.2μmol/L. Abdominal US revealed the disappearance of the previous multiple hypoechoic nodular lesions (Figure 1B). A repeated liver biopsy showed spot necrosis and partial cholestasis with some neutrophil and eosinophil leucocytes infiltration in the portal space (Figure 2B).
A second course of anthelmintic treatment (albendazole, 400mg/day) was given for another 14 days. Six months after the second course, a laboratory evaluation showed: WBC 9.3 × 109/L with 10.6% eosinophils, ALT 45U/L, AST 42U/L, GGT 68U/L, TB 28.5μmol/L, DB 13.0μmol/L and IB 15.5μmol/L. No parasite ova or larvae were detected in a repeated stool examination. A repeated abdominal US and bone marrow biopsy were normal. A third liver biopsy showed hepatocyte edema accompanied by mild neutrophil and eosinophil leukocyte infiltration in the portal space, but no necrosis was observed (Figure 2C).
A third course of anthelmintic therapy (albendazole, 400mg/day) was administrated for an additional seven days. Two weeks later, praziquantel was prescribed at a dosage of 1g twice daily for three days (120mg/kg, the fourth course). Two weeks after the fourth course, the laboratory examination results were almost normal except for slightly elevated eosinophil percentage (6.6%). Three months later, our patient presented with increased physical activities and his laboratory data all returned to a normal range (WBC 6.5 × 109/L with 4.0% eosinophils, ALT 27U/L and AST 25U/L).
VLM was first described by Beaver et al. in a case series of some children who presented with fever, hepatomegaly, pulmonary infiltration and peripheral eosinophilia as a result of Toxocara canis infection . Subsequently, several kinds of parasites, such as T. cati Ascaris suum Capillaria hepatica Gnathostoma spinigerum Spirometra mansoni Angiostrongylus cantonensis Pagumogonimus skrjabini and some Ancylostoma species, have been reported to cause VLM [4, 5]. Because humans are unsuitable hosts for larval helminths, the parasites, once entering, migrate without growing among the various organs, such as the liver, lungs, brain and eyes, leading to tissue damage and inflammation with eosinophilic infiltration. Among the visceral organs involved, the liver is most commonly affected, due to the portal venous drainage of visceral organs . When larvae penetrate the wall of the gut, gaining access to the portal venous circulation, they move through the liver and induce liver parenchyma necrosis, interstitial edema, hemorrhage and eosinophilic exudates. In addition, their released antigens can stimulate the host immune system, resulting in fever, marked eosinophilia and hyperglobulinemia .
Clinical manifestations of VLM involving the liver include fever, fatigue, abdominal pain and hepatomegaly . Laboratory evaluation of patients with VLM almost always reveals leukocytosis with notable eosinophilia and elevated transaminase levels . Sonographic findings of hepatic VLM are multiple ill-defined oval or elongated small nodular lesions scattered in the liver parenchyma . A typical liver biopsy shows central necrosis surrounded by a mixed inflammatory infiltrate with numerous eosinophils and variable numbers of neutrophils, lymphocytes and Charcot-Leyden crystals, which is strongly suggestive of VLM . In this case, our patient had partial clinical manifestations of VLM involving the liver, including fatigue, eosinophilia, elevated transaminase levels, hepatic nodular lesions and typical pathological characteristics. These manifestations led to a diagnosis of hepatic VLM.
However, the diagnosis of VLM should not be just based on typical clinical manifestations. The definite diagnosis of parasite infection should be based on detected worms or eggs, but the causative parasites of VLM are difficult to find. Larval helminths in aberrant hosts are unable to fully mature and reproduce, which makes the stool examination for ova invalid. Furthermore, due to their tiny size and rapid movement in tissues, the larvae are rarely observed in pathologic examination . Therefore, positive serological test results are generally accepted as an indirect method to identify the causative parasite. In this case, a positive serum reaction against Paragonimus antigen suggested Paragonimus infection. Our patient was from Hainan province in China, where the soil-transmitted parasite is endemic. He also had a history of multiple ingestion of live earthworms and geckos, which can serve as paratenic carriers of soil-transmitted larval helminths such as Toxocara larvae and which can carry contaminated soil. Given these factors, soil-transmitted larval helminth infection should be taken into consideration regardless of the negative serological test results . Similarly, in 2006 Cianferoni et al. reported the case of a patient with VLM involving the lung and liver through Toxocara infection resulting from earthworm ingestion .
In clinical situations, VLM is frequently suspected to be caused by more than one kind of parasite infection. Furthermore, soil-transmitted zoonosis is primarily caused by Nemata larval infection and more commonly seen involving hepatic damage than Paragonimus. Because albendazole is an effective and relatively safe drug against Nemata larvae, the first course of anthelmintic therapy administrated in this case was high-dose albendazole . A good clinical response to albendazole treatment was obtained, indicating a correct diagnosis of VLM. After four courses of high-dose anthelmintic therapy (albendazole and praziquantel), all clinical symptoms were improved. The notable eosinophilia gradually disappeared and the elevated transaminase level steadily returned to a normal range. Moreover, the normalization of his bone marrow and liver, shown by examination of the repeated biopsy specimens, also provided evidence for the positive effect of anthelmintic therapy. These favorable clinical responses further confirmed the diagnosis of VLM.
We present the case of a patient suspected of having VLM involving his liver, resulting from earthworm and gecko ingestion. Our patient’s positive clinical response to multiple anthelmintic therapies with albendazole and praziquantel confirmed the diagnosis of VLM. Due to the difficulty in making a definite diagnosis, anthelmintic therapy should be administered to patients suspected of having VLM according to their epidemic history and presence of typical manifestations, including when serological tests are negative. Furthermore, patients with VLM with severe parasite infection may require multiple anthelmintic therapies to eliminate the parasites.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Kayes SG: Human toxocariasis and the visceral larva migrans syndrome: correlative immunopathology. Chem Immunol. 1997, 66: 99-124.View ArticlePubMedGoogle Scholar
- Turrientes MC, Perez de Ayala A, Norman F, Navarro M, Perez-Molina JA, Rodriquez-Ferrer M, Garate T, Lopez-Velez R: Visceral larva migrans in immigrants from Latin America. Emerg Infect Dis. 2011, 17: 1263-1265. 10.3201/eid1707.101204.View ArticlePubMedPubMed CentralGoogle Scholar
- Uhlíková M, Hübner J, Kolárová L, Polácková M: Immunological studies on human larval toxocarosis. Cent Eur J Public Health. 1996, 4: 242-245.PubMedGoogle Scholar
- Sakakibara A, Baba K, Niwa S, Yagi T, Wakayama H, Yoshida K, Kobayashi T, Yokoi T, Hara K, Itoh M, Kimura E: Visceral larva migrans due to Ascaris suum which presented with eosinophilic pneumonia and multiple intra-hepatic lesions with severe eosinophil infiltration–outbreak in a Japanese area other than Kyushu. Intern Med. 2002, 41: 574-579. 10.2169/internalmedicine.41.574.View ArticlePubMedGoogle Scholar
- Li DM, Chen XR, Zhou JS, Xu ZB, Nawa Y, Dekumyoy P: Short report: case of gnathostomiasis in Beijing, China. Am J Trop Med Hyg. 2009, 80: 185-187.PubMedGoogle Scholar
- Graeff-Teixeira C, da Silva AC, Yoshimura K: Update on eosinophilic meningoencephalitis and its clinical relevance. Clin Microbiol Rev. 2009, 22: 322-348. 10.1128/CMR.00044-08.View ArticlePubMedPubMed CentralGoogle Scholar
- Lim JH: Toxocariasis of the liver: visceral larva migrans. Abdom Imaging. 2008, 33: 151-156. 10.1007/s00261-007-9325-y.View ArticlePubMedGoogle Scholar
- Arango CA: Visceral larva migrans and the hypereosinophilia syndrome. South Med J. 1998, 91: 882-883. 10.1097/00007611-199809000-00019.View ArticlePubMedGoogle Scholar
- Chang S, Lim JH, Choi D, Park CK, Kwon NH, Cho SY, Choi DC: Hepatic visceral larva migrans of Toxocara canis: CT and sonographic findings. AJR Am J Roentgenol. 2006, 187: W622-W629. 10.2214/AJR.05.1416.View ArticlePubMedGoogle Scholar
- Kaplan KJ, Goodman ZD, Ishak KG: Eosinophilic granuloma of the liver: a characteristic lesion with relationship to visceral larva migrans. Am J Surg Pathol. 2001, 25: 1316-1321. 10.1097/00000478-200110000-00014.View ArticlePubMedGoogle Scholar
- Pahari TK, Sasmal NK: Experimental infection of Japanese quail with Toxocara canis larvae through earthworms. Vet Parasitol. 1991, 39: 337-340. 10.1016/0304-4017(91)90051-V.View ArticlePubMedGoogle Scholar
- Cianferoni A, Schneider L, Schantz PM, Brown D, Fox LM: Visceral larva migrans associated with earthworm ingestion: clinical evolution in an adolescent patient. Pediatrics. 2006, 117: e336-e339. 10.1542/peds.2005-1596.View ArticlePubMedGoogle Scholar
- Bhatia V, Sarin SK: Hepatic visceral larva migrans: evolution of the lesion, diagnosis, and role of high-dose albendazole therapy. Am J Gastroenterol. 1994, 89: 624-627.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.